All In Biotech

Free tool

FAERS Monitor: Aqneursa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219132 or its brand name (Aqneursa, Levacetylleucine). Reports on generic versions are filed under their own applications.

Reports

251

Serious

63

25% of reports

Hospitalization

26

Death reported

14

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use140
  • fall11
  • product use in unapproved indication11
  • seizure11
  • vomiting9
  • dysphagia8
  • pneumonia8
  • gait disturbance7
  • pneumonia aspiration7
  • decreased appetite6
  • diarrhoea6
  • product use issue6
  • death5
  • drug ineffective5
  • insomnia5

Reports by year received

View as table
YearReports
20201
20231
20247
2025151
202691

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,908 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pneumonia aspirationSignal723.511.3129
off label useSignal14013.412.01,663
seizureSignal118.04.561
dysphagiaSignal87.13.636
product use in unapproved indicationSignal113.72.119
gait disturbanceSignal73.11.58
fallSignal112.81.611
product use issueSignal62.71.25
decreased appetite62.21.03
pneumonia82.11.03
vomiting91.60.82
insomnia51.60.71
diarrhoea60.80.40
death50.50.22
drug ineffective50.30.17

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.